Selective Use of Staging Laparoscopy Based on Carbohydrate Antigen 19-9 Level and Tumor Size in Patients With Radiographically Defined Potentially or Borderline Resectable Pancreatic Cancer
- 1 April 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 40 (3), 426-432
- https://doi.org/10.1097/mpa.0b013e3182056b1c
Abstract
The aims of this study were to verify whether the selective use of staging laparoscopy can prevent unnecessary laparotomy and to find a surrogate marker for surgical unresectability in patients with potentially or borderline resectable pancreatic cancer. Group A consisted of consecutive 33 patients evaluated between 2005 and 2006 and who directly underwent open laparotomy for planned surgical resection. Group B consisted of consecutive 61 patients evaluated between 2007 and 2009 and of whom 16 patients (26%) had a staging laparoscopy due to the presence of high-risk markers of unresectability defined as carbohydrate antigen 19-9 level 150 U/mL or greater and tumor size 30 mm or greater. The frequency of unnecessary laparotomies for occult distant organ metastasis was significantly different between groups A and B (18% and 3%, respectively; P = 0.021). Of 16 patients who underwent staging laparoscopy in group B, 5 patients (31%) had occult metastases. The multivariate analysis showed that the presence of high-risk markers and extrapancreatic plexus invasion on multidetector-row computed tomography were significant independent risk factors for unresectability. The presence of high-risk markers was associated with surgical unresectability in patients with potentially or borderline resectable pancreatic cancer. The selective use of staging laparoscopy decreased the frequency of unnecessary laparotomy by detecting minute metastases.Keywords
This publication has 26 references indexed in Scilit:
- Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic CancerAnnals of Surgery, 2009
- Surgical Results After Preoperative Chemoradiation Therapy for Patients With Pancreatic CancerPancreas, 2009
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic HeadJournal of Clinical Oncology, 2008
- Current Utility of Staging Laparoscopy for Pancreatic and Peripancreatic NeoplasmsJournal of the American College of Surgeons, 2008
- Clinical Impact of Multidetector Row Computed Tomography on Patients With Pancreatic CancerPancreas, 2007
- Pancreatic cancerThe Lancet, 2004
- Clinicopathologic Evaluation After Resection for Ductal Adenocarcinoma of the Pancreas: A Retrospective, Single-Institution ExperiencePancreas, 2003
- Prognostic Factors Following Curative Resection for Pancreatic AdenocarcinomaAnnals of Surgery, 2003
- Pancreaticoduodenectomy With or Without Distal Gastrectomy and Extended Retroperitoneal Lymphadenectomy for Periampullary Adenocarcinoma, Part 2Annals of Surgery, 2002
- Standard Versus Extended Lymphadenectomy Associated With Pancreatoduodenectomy in the Surgical Treatment of Adenocarcinoma of the Head of the PancreasAnnals of Surgery, 1998